Journal
PHARMACEUTICAL RESEARCH
Volume 28, Issue 5, Pages 949-961Publisher
SPRINGER/PLENUM PUBLISHERS
DOI: 10.1007/s11095-011-0414-9
Keywords
aggregation; biotherapeutics; cross beta motif; drug development; immunogenicity
Funding
- Pfizer
Ask authors/readers for more resources
Biotherapeutics, including recombinant or plasma-derived human proteins and antibody-based molecules, have emerged as an important class of pharmaceuticals. Aggregation and immunogenicity are among the major bottlenecks during discovery and development of biotherapeutics. Computational tools that can predict aggregation prone regions as well as T- and B-cell immune epitopes from protein sequence and structure have become available recently. Here, we describe a potential coupling between aggregation and immunogenicity: T-cell and B-cell immune epitopes in therapeutic proteins may contain aggregation-prone regions. The details of biological mechanisms behind this observation remain to be understood. However, our observation opens up an exciting potential for rational design of de-immunized novel, as well as follow on biotherapeutics with reduced aggregation propensity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available